ABSENCE OF PREFERENTIAL UPTAKE OF [I-125]IODODIHYDRORHODAMINE 123 BY 4 HUMAN-TUMOR XENOGRAFTS

被引：0
|
作者：
KINSEY, BM [1 ]
VANDENABBEELE, AD [1 ]
ADELSTEIN, SJ [1 ]
KASSIS, AI [1 ]
机构：
[1] HARVARD UNIV,SCH MED,DEPT RADIOL NUCL MED,SHIELDS WARREN RADIAT LAB,50 BINNEY ST,BOSTON,MA 02115
来源：
CANCER RESEARCH | 1989年 / 49卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：5986 / 5988
页数：3
相关论文
共 50 条
  • [31] TISSUE UPTAKE OF I-125 BETA-2-MICROGLOBULIN (BETA-2-M) IN ANEPHRIC ANIMALS IN THE PRESENCE OR ABSENCE OF ALUMINUM INTOXICATION
    URENA, P
    ZINGRAFF, J
    NOEL, LH
    BARDIN, T
    DRUEKE, T
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1988, 3 (05) : 632 - 636
  • [32] RADIOIMMUNODETECTION (RID) OF HUMAN SOLID TUMOR XENOGRAFTS BY 125I-TURP-73 MONOCLONAL-ANTIBODY (MAB)
    COX, AD
    WRIGHT, GL
    STARLING, JJ
    FEDERATION PROCEEDINGS, 1987, 46 (04) : 1508 - 1508
  • [33] DIFFERENTIAL RESPONSE OF 4 HUMAN-TUMOR XENOGRAFTS IMPLANTED IN THE SAME HOST TO HIGH-DOSE METHOTREXATE AND CALCIUM LEUCOVORIN RESCUE
    KRISHAN, A
    GANAPATHI, R
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 241 - 241
  • [34] Imaging and biodistribution of I-125 tyramine oligonucleotide in nude mice bearing human breast tumor. Preliminary report
    Cammilleri, S
    Perdereau, B
    Brixy, F
    Pierga, JY
    Benyahia, B
    Chypre, C
    Magdelenat, H
    BULLETIN DU CANCER, 1996, 83 (01) : 23 - 26
  • [35] THERAPY WITH I-125 LABELED INTERNALIZED AND NON-INTERNALIZED MONOCLONAL-ANTIBODIES IN NUDE-MICE WITH HUMAN COLON-CARCINOMA XENOGRAFTS
    ARONSSON, EF
    GRETARSDOTTIR, J
    JACOBSSON, L
    BACK, T
    HERTZMAN, S
    LINDEGREN, S
    KARLSSON, B
    LINDHOLM, L
    HOLMBERG, S
    HAFSTROM, L
    MATTSSON, S
    NUCLEAR MEDICINE AND BIOLOGY, 1993, 20 (02) : 133 - 144
  • [36] PREPARATION AND QUALITY-CONTROL OF AT-211-LABELED AND I-125 LABELED MONOCLONAL-ANTIBODIES - BIODISTRIBUTION IN MICE CARRYING HUMAN OSTEOSARCOMA XENOGRAFTS
    LARSEN, RH
    HOFF, P
    ALSTAD, J
    BRULAND, OS
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 1994, 34 (08): : 773 - 785
  • [37] TUMOR KINETICS AND TIMING OF THE 2ND DOSE TO IMPROVE TUMOR RADIOCURABILITY - A PREDICTION OF THE BEST TIMING FOR FRACTIONATION BY MEASURING I-125 IODODEOXY URIDINE UPTAKE INSITU
    TAKAI, Y
    SAKAMOTO, K
    OKADA, S
    ONCOLOGY, 1993, 50 (02) : 141 - 147
  • [38] DISTRIBUTION OF IN-111-LABELED AND I-125 LABELED MONOCLONAL-ANTIBODY 17-1A IN MICE BEARING XENOGRAFTS OF HUMAN PANCREATIC-CARCINOMA HUP-T4
    MAEDA, M
    SHOJI, M
    KAWAGOSHI, T
    FUTATSUYA, R
    HONDA, T
    BRADY, LW
    CANCER, 1994, 73 (03) : 800 - 807
  • [39] Tumor uptake and mitotic activity pattern of 5-[I-125]iodo-2'-deoxyuridine after intravesical infusion in patients with bladder cancer
    Mariani, G
    Collecchi, P
    Baldassarri, S
    DiLuca, L
    Buralli, S
    Fontanini, G
    BaranowskaKortylewicz, J
    Adelstein, SJ
    Kassis, AI
    JOURNAL OF NUCLEAR MEDICINE, 1996, 37 (04) : S16 - S19
  • [40] Increased binding to sigma sites of N-[1′(2-piperidinyl)ethyl]-4-[I-125]-iodobenzamide (I-125-PAB) with onset of tumor cell proliferation
    Zamora, PO
    Moody, TW
    John, CS
    LIFE SCIENCES, 1998, 63 (18) : 1611 - 1618
12345